Dentons Lee signed an MOU with new drug developer Pharos iBio Co., Ltd. On December 7th.

Pharos iBio is an AI platform-based new drug development company. It is a proven company which is currently conducting phase 1 clinical trials for acute myeloid leukemia (AML) treatment in multinational level (Korea, Australia, Spain) and domestic phase 1 clinical trials for recurrent ovarian cancer (OC) treatment, using various new drug databases.

Recently, Pharos iBio has successfully attracted investment worth around 60 billion won from institutional investors for expanding global clinical trials and building new pipelines.

On this, Dentons Lee will give an active and preemptive support and cooperation in various tasks that the firm can provide, including legal/investment/listing advice, dispute resolution and IP advisory services to be required for Pharos iBio’s overseas expansion.

About Dentons

Across over 80 countries, Dentons helps you grow, protect, operate and finance your organization by providing uniquely global and deeply local legal solutions. Polycentric, purpose-driven and committed to inclusion, diversity, equity and sustainability, we focus on what matters most to you. www.dentons.com